Cannabis treatment was associated with “significant improvements in all primary outcomes … at all timepoints,” authors reported.
Archives: News Releases
Since 1992, every Thursday and when breaking news warrants, NORML | The NORML Foundation have been issuing weekly press releases for marijuana law supporters and the media.
NORML’s News Releases archives goes back to 1996 and serves as a valuable tool to alert citizens about cannabis-related news and legislation as well as a research tool for reviewing a chronology of marijuana law reform.
Patients with a history of cannabis use had significantly shorter length of stay and higher rates of home discharge following primary TJA compared to the control group.”
“Transitioning consumers of all cannabis products into the regulated market is important for public health and safety,” the authors affirmed.
Over 90 percent of respondents said that cannabis use reduced their average pain by at least half.
“[I]n human volunteers, THC has no significant effect on ventilatory control after placebo or oxycodone pretreatment,” investigators concluded.
“CBD may be appropriate for RAU patients who choose not to take topical steroids,” scientists concluded.
Researchers reported, “Symptom relief was greatest after consumption of plant variants with slightly higher than average levels of the terpenes myrcene and terpinolene.”
Investigators reported reductions in patients’ agitation, apathy, irritability, sleep disturbances, and eating disturbances following cannabis treatment.